SEP 25, 2020 7:00 AM PDT

Ray of Hope: Rare Cancer Biomarker Discovered

WRITTEN BY: Tara Fernandez

Biliary tract cancer, or BTC, isn’t as talked about as breast or prostate cancers, probably because its incidence is much rarer. BTCs are a group of gastrointestinal tumors including gallbladder cancers whose prevalence is increasing in South America and Asia. In Western countries, only around 1.6 in every 100,000 get diagnosed with the disease, but when they do, the mortality rate is staggeringly high: most patients die within 1 year of starting chemo.

A team of Danish researchers has identified a silver lining for BTC patients — a biomarker that can serve as a barometer for how aggressive the cancer is.

Speaking on the significance of the discovery, Jesper Andersen, one of the scientists leading the study said: "We have found a biomarker that reliably predicts how aggressively a patient’s disease will evolve, which in the future could help doctors in the hospitals make the right decisions about chemotherapy for the benefit of each BTC patient." 

The new metric involves quantifying the levels of two inflammatory proteins, interleukin-6 (IL-6) and YKL-40 during the patient’s journey from the initial diagnosis to the initiation of chemotherapy and beyond. Despite being incredibly rare, the researchers managed to obtain over 1500 blood samples from 452 patients diagnosed with advanced BTC. A study of this magnitude is unprecedented in the field and may prove to be transformative in improving BTC patient outcomes in the long run.

The team also uncovered another utility for targeting IL-6 beyond the scope of a diagnostic. In mouse models of BTC, blocking the cellular signaling pathways controlled by IL-6 dramatically improved the reduction in tumor size following chemotherapy.

 

Source: MedicalXpress, Clinical Cancer Research.

About the Author
  • Tara Fernandez has a PhD in Cell Biology and has spent over a decade uncovering the molecular basis of diseases ranging from skin cancer to obesity and diabetes. She currently works on developing and marketing disruptive new technologies in the biotechnology industry. Her areas of interest include innovation in molecular diagnostics, cell therapies, and immunology. She actively participates in various science communication and public engagement initiatives to promote STEM in the community.
You May Also Like
DEC 23, 2020
Clinical & Molecular DX
Smartphone Device Uses CRISPR to Check for COVID
DEC 23, 2020
Smartphone Device Uses CRISPR to Check for COVID
Quick, portable, and ultrasensitive—a new smartphone test for COVID-19 checks all the boxes needed to get a handle ...
DEC 30, 2020
Neuroscience
Brain Imaging Predicts Risk of PTSD
DEC 30, 2020
Brain Imaging Predicts Risk of PTSD
Until now, why posttraumatic stress disorder (PTSD) develops in some and not others following a physical and/ or psychol ...
JAN 24, 2021
Genetics & Genomics
Rare Neurodevelopment Disorder LINKED is IDed
JAN 24, 2021
Rare Neurodevelopment Disorder LINKED is IDed
Scientists have now characterized a genetic disorder called linkage-specific-deubiquitylation-deficiency-induced embryon ...
MAR 18, 2021
Cardiology
Searching for New Cardiovascular Biomarkers
MAR 18, 2021
Searching for New Cardiovascular Biomarkers
Do you want to know what the best medicine for cardiovascular health is? It isn't some heart-shaped pill with some m ...
APR 22, 2021
Clinical & Molecular DX
Gum Disease Makes COVID Patients More Likely to Die
APR 22, 2021
Gum Disease Makes COVID Patients More Likely to Die
Gum disease is associated with an increased risk of COVID-related ICU admission and death, says a study by McGill Univer ...
APR 27, 2021
Clinical & Molecular DX
No Batteries: Health Sensor Harvests Biomechanical Energy
APR 27, 2021
No Batteries: Health Sensor Harvests Biomechanical Energy
An international team of researchers has developed a wearable health monitor that works without the need for batteries. ...
Loading Comments...